Vandetanib
1
Reactions 1396 - 7 Apr 2012 ★ Vandetanib First report of vortex keratopathy: case report A 44-year-old woman with non-small cell lung cancer was enrolled in a clinical trial for vandetanib and began receiving one-month cycles of vandetanib 300 mg/day [route not stated]. She presented with fogged vision after six cycles. On examination, a diffuse subepithelial haze and inferior subepithelial whorls were evident in both corneas on fundoscopy. Other examinations showed normal findings. Artificial tears were recommended, but she decided against topical therapy and was scheduled for follow-up in 3 months; vandetanib therapy was continued without dosage reduction. Author comment: "Stopping or reducing the dose of vandetanib would have provided better evidence for the establishment of a causal relationship between vandetanib use and vortex keratopathy. Nevertheless, it may be reasonable to assume that vortex keratopathy with subepithelial haziness was induced by vandetanib in this case." Ahn J, et al. Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer. Korean Journal of Ophthalmology 25: 355-7, No. 5, Oct 2011 - South Korea 803068930 » Editorial comment: A search of AdisBase, Medline and Embase did not reveal any previous case reports of vortex keratopathy associated with vandetanib. The WHO ADR database contained no reports of keratopathy associated with vandetanib. 1 Reactions 7 Apr 2012 No. 1396 0114-9954/10/1396-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Vandetanib
Reactions 1396 - 7 Apr 2012
★Vandetanib
First report of vortex keratopathy: case reportA 44-year-old woman with non-small cell lung cancer
was enrolled in a clinical trial for vandetanib and beganreceiving one-month cycles of vandetanib 300 mg/day[route not stated]. She presented with fogged vision aftersix cycles. On examination, a diffuse subepithelial haze andinferior subepithelial whorls were evident in both corneason fundoscopy. Other examinations showed normalfindings. Artificial tears were recommended, but shedecided against topical therapy and was scheduled forfollow-up in 3 months; vandetanib therapy was continuedwithout dosage reduction.
Author comment: "Stopping or reducing the dose ofvandetanib would have provided better evidence for theestablishment of a causal relationship between vandetanibuse and vortex keratopathy. Nevertheless, it may bereasonable to assume that vortex keratopathy withsubepithelial haziness was induced by vandetanib in thiscase."Ahn J, et al. Vortex keratopathy in a patient receiving vandetanib for non-smallcell lung cancer. Korean Journal of Ophthalmology 25: 355-7, No. 5, Oct 2011 -South Korea 803068930
» Editorial comment: A search of AdisBase, Medline andEmbase did not reveal any previous case reports of vortexkeratopathy associated with vandetanib. The WHO ADRdatabase contained no reports of keratopathy associatedwith vandetanib.
1
Reactions 7 Apr 2012 No. 13960114-9954/10/1396-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
